To test this hypothesis, we examined genome-wide chromatin accessibility using assay for transposase-accessible chromatin with sequencing (ATAC-seq) to determine whether gilteritinib can remodel the chromatin landscape in leukemia cells of an AML case with mutations in the FLT3 TKD. Here, FLT3 is linked to acute myeloid leukemia.